CN101341170B - 抗白介素-22结合蛋白的抗体及其用途 - Google Patents
抗白介素-22结合蛋白的抗体及其用途 Download PDFInfo
- Publication number
- CN101341170B CN101341170B CN2006800482864A CN200680048286A CN101341170B CN 101341170 B CN101341170 B CN 101341170B CN 2006800482864 A CN2006800482864 A CN 2006800482864A CN 200680048286 A CN200680048286 A CN 200680048286A CN 101341170 B CN101341170 B CN 101341170B
- Authority
- CN
- China
- Prior art keywords
- antibody
- mouse
- interleukin
- purifying
- binding protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims (3)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75239705P | 2005-12-22 | 2005-12-22 | |
US60/752,397 | 2005-12-22 | ||
PCT/US2006/062450 WO2007076422A2 (en) | 2005-12-22 | 2006-12-21 | Antibodies against interleukin-22 binding protein and its uses |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101341170A CN101341170A (zh) | 2009-01-07 |
CN101341170B true CN101341170B (zh) | 2013-02-13 |
Family
ID=38218823
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2006800482864A Expired - Fee Related CN101341170B (zh) | 2005-12-22 | 2006-12-21 | 抗白介素-22结合蛋白的抗体及其用途 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20090148440A1 (zh) |
EP (1) | EP1969008A4 (zh) |
JP (1) | JP2009521503A (zh) |
CN (1) | CN101341170B (zh) |
AU (1) | AU2006330573A1 (zh) |
CA (1) | CA2634262A1 (zh) |
WO (1) | WO2007076422A2 (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104302780B (zh) * | 2011-08-05 | 2017-04-12 | 艾克斯-马赛大学 | 纤维变性易感性il22ra2基因及其用途 |
CN110157733A (zh) * | 2018-02-11 | 2019-08-23 | 四川大学 | 重组mIL-22BP载体、脂质体复合物及其制备方法和用途 |
WO2021241730A1 (ja) * | 2020-05-29 | 2021-12-02 | 第一三共株式会社 | 炎症性腸疾患に対する治療用抗体 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002024912A2 (en) * | 2000-09-22 | 2002-03-28 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules which encode a soluble il-tif/il-22 receptor or binding protein which binds to il-tif/il-22, and uses thereof |
US6740520B2 (en) * | 2000-03-21 | 2004-05-25 | Genentech, Inc. | Cytokine receptor and nucleic acids encoding the same |
US20040209330A1 (en) * | 2003-03-24 | 2004-10-21 | Wenfeng Xu | Anti-IL-22RA antibodies and binding partners and methods of using in inflammation |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4849227A (en) * | 1986-03-21 | 1989-07-18 | Eurasiam Laboratories, Inc. | Pharmaceutical compositions |
US5116964A (en) * | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
US5541087A (en) * | 1994-09-14 | 1996-07-30 | Fuji Immunopharmaceuticals Corporation | Expression and export technology of proteins as immunofusins |
US20010023070A1 (en) * | 1998-05-29 | 2001-09-20 | Reinhard Ebner | Interleukins-21 and 22 |
US7094570B2 (en) * | 2003-03-11 | 2006-08-22 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules which encode a soluble IL-TIF/IL-22 receptor or binding protein which binds to IL-TIF/IL-22, and uses thereof |
US20030235561A1 (en) * | 2002-06-25 | 2003-12-25 | Cell Based Delivery Inc. | Vascularized organized tissues and uses thereof |
-
2006
- 2006-12-21 JP JP2008547761A patent/JP2009521503A/ja active Pending
- 2006-12-21 CN CN2006800482864A patent/CN101341170B/zh not_active Expired - Fee Related
- 2006-12-21 AU AU2006330573A patent/AU2006330573A1/en not_active Abandoned
- 2006-12-21 WO PCT/US2006/062450 patent/WO2007076422A2/en active Application Filing
- 2006-12-21 US US12/096,180 patent/US20090148440A1/en not_active Abandoned
- 2006-12-21 EP EP06840335A patent/EP1969008A4/en not_active Withdrawn
- 2006-12-21 CA CA002634262A patent/CA2634262A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6740520B2 (en) * | 2000-03-21 | 2004-05-25 | Genentech, Inc. | Cytokine receptor and nucleic acids encoding the same |
WO2002024912A2 (en) * | 2000-09-22 | 2002-03-28 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules which encode a soluble il-tif/il-22 receptor or binding protein which binds to il-tif/il-22, and uses thereof |
US20040209330A1 (en) * | 2003-03-24 | 2004-10-21 | Wenfeng Xu | Anti-IL-22RA antibodies and binding partners and methods of using in inflammation |
Also Published As
Publication number | Publication date |
---|---|
WO2007076422A3 (en) | 2007-11-01 |
WO2007076422A2 (en) | 2007-07-05 |
EP1969008A4 (en) | 2009-08-12 |
EP1969008A2 (en) | 2008-09-17 |
AU2006330573A1 (en) | 2007-07-05 |
JP2009521503A (ja) | 2009-06-04 |
CN101341170A (zh) | 2009-01-07 |
CA2634262A1 (en) | 2007-07-05 |
US20090148440A1 (en) | 2009-06-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210403525A1 (en) | Targeted mutant interferon-gamma and uses thereof | |
US11384154B2 (en) | Targeted chimeric proteins and uses thereof | |
CN109689087A (zh) | 靶向性突变干扰素-β及其用途 | |
US11873349B1 (en) | Compositions and methods related to IL27 receptor binding | |
CN109563141A (zh) | 对非细胞结构的治疗性靶向 | |
CN111902428B (zh) | 一种双特异性抗体及其用途 | |
CA2430135A1 (en) | Recombinant anti-cd30 antibodies and uses thereof | |
AU2014269287B2 (en) | Anti-TNF-alpha/CXCL10 double-targeting antibody and use thereof | |
KR20080022539A (ko) | 키메라 단백질 | |
CN106068125B (zh) | 治疗脂肪组织积聚的组合物和方法 | |
US20230272090A1 (en) | Il2rb binding molecules and methods of use | |
CN111375059B (zh) | 一种抗gitr抗体药物组合物及其用途 | |
CN101341170B (zh) | 抗白介素-22结合蛋白的抗体及其用途 | |
JP2002527403A (ja) | リンホトキシンβ経路の遮断によるウイルス誘導性全身性ショックおよび呼吸窮迫の逆転 | |
US11680102B2 (en) | Anti-BAFF receptor antibodies and uses thereof | |
CN109153718A (zh) | 抗TNFα抗体及其功能片段 | |
TWI825214B (zh) | 抗TNFα/抗IL-17A天然抗體結構樣異源二聚體形式雙特異抗體及其製備 | |
CN108601819B (zh) | 用死亡受体激动剂改善系统性硬化症 | |
KR20210021861A (ko) | 사람 표피성장인자수용체 2 양성 암을 치료하기 위한 인터페론-베타 변이체 면역사이토카인의 용도 및 환자 선별 방법 | |
TW202321459A (zh) | 可活化治療劑相關之組合物及方法 | |
Lee et al. | Development and characterization of mouse monoclonal antibodies reactive with chicken TL1A | |
CN116375871A (zh) | 抗gitr抗体及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: GENERON (SHANGHAI) CORPORATION LTD. Effective date: 20110830 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; TO: 201203 PUDONG NEW AREA, SHANGHAI |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20110830 Address after: 201203, 302/303, room 9, 1011, Harley Road, Zhangjiang hi tech park, Shanghai Applicant after: Generon (Shanghai) Corporation Ltd. Address before: The British Virgin Islands of Tortola Applicant before: Dhy & Co., Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: BEIJING GENERON BIOLOGICAL MEDICINE TECHNOLOGY CO. Free format text: FORMER OWNER: JIANNENGLONG MEDICAL TECHNOLOGY (SHANGHAI) CO., LTD. Effective date: 20131128 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 201203 PUDONG NEW AREA, SHANGHAI TO: 100083 HAIDIAN, BEIJING |
|
TR01 | Transfer of patent right |
Effective date of registration: 20131128 Address after: 100083 Beijing City, Haidian District Xueyuan Road No. 30, large industrial building A block 4 layer 01, room 19 Patentee after: Beijing Jian long biological medicine technology Co., Ltd. Address before: 201203, 302/303, room 9, 1011, Harley Road, Zhangjiang hi tech park, Shanghai Patentee before: Generon (Shanghai) Corporation Ltd. |
|
ASS | Succession or assignment of patent right |
Owner name: JIANNENGLONG MEDICAL TECHNOLOGY (SHANGHAI) CO., LT Free format text: FORMER OWNER: BEIJING GENERON BIOLOGICAL MEDICINE TECHNOLOGY CO., LTD. Effective date: 20150701 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20150701 Address after: 201215, building 787, 9 Cambridge Road, Shanghai, Pudong New Area Patentee after: Generon (Shanghai) Corporation Ltd. Address before: 100083 Beijing City, Haidian District Xueyuan Road No. 30, large industrial building A block 4 layer 01, room 19 Patentee before: Beijing Jian long biological medicine technology Co., Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130213 Termination date: 20181221 |
|
CF01 | Termination of patent right due to non-payment of annual fee |